Indiana University School of Medicine
Thomas A. Gardner, M.D.
535 N. Barnhill Dr. Indianapolis, IN 46202
NAME:
Gardner, Thomas
EDUCATION:
UNDERGRADUATE:
The George Washington University
Columbian College of Arts and Science
Washington, D.C.
1986, B.A. “with Distinction”
Major: Computer Science / Statistics
GRADUATE:
The George Washington University
School of Medicine
Washington, D.C.
1990, M.D.
POSTDOCTORAL:
1990-1991
1991-1992
1992-1995
1993
1992-1996
1995-1996
Intern, General Surgery
New York Hospital-Cornell Medical Center, New York, NY
Breast and Thoracic Surgery Rotations-Memorial Sloan-Kettering Cancer Center
Resident, General Surgery
New York Hospital-Cornell Medical Center, New York, NY
Thoracic Surgery Rotations-Memorial Sloan-Kettering Cancer Center
Resident, Urology
New York Hospital-Cornell Medical Center, New York, NY
Urologic Surgery Rotation-Memorial Sloan-Kettering Cancer Center
Research Rotation
New York Hospital-Cornell Medical Center, New York, NY
Urologic Oncology Lab (Director: Neil H. Bander) and Male Reproductive
Microsurgery & Reconstructive Training Lab (Director Marc Goldstein)
Lecturer and Clinical Instructor
Cornell University Medical College-Physician Assistant Program, New York,NY
Chief Resident, Urology
New York Hospital-Cornell Medical Center, New York, NY
1996-1998
Urologic Oncology Research Fellowship
Cancer Biology/Gene Therapy
Lab Director: Leland W. K. Chung, Ph.D.
Department of Urology, Molecular Urology and Therapeutics Program,
University of Virginia Health Sciences Center
Charlottesville, VA
ACADEMIC APPOINTMENTS: (Inclusive dates.)
1998-1999
Assistant Professor of Research
Department of Urology, Molecular Urology and Therapeutics Program,
University of Virginia Health Sciences Center,
Charlottesville, VA
P&T Dossier CV 03/2010
Page
1
Thomas A. Gardner, M. D.
1999- 2001
1999-2005
1999 -2005
2005-Present
2005-Present
Visiting Assistant Professor
Department of Urology, Molecular Urology and Therapeutics Program,
University of Virginia Health Sciences Center,
Charlottesville, VA
Assistant Professor of Urology,
Indiana University, School of Medicine
Indianapolis, IN
Assistant Professor of Microbiology and Immunology
Indiana University, School of Medicine
Indianapolis, IN
Associate Professor of Urology with Tenure,
Indiana University, School of Medicine
Indianapolis, IN
Associate Professor of Microbiology and Immunology
Indiana University, School of Medicine
Indianapolis, IN
HOSPITAL APPOINTMENTS:
1999 – Present Attending Urologist
Indiana University Medical Center, Indianapolis, IN
1999 - Present Urology Staff Surgeon and Service Chief (1999-2007)
Department of Surgery,Wishard Memorial Hospital,
Indianapolis, IN
1999 - Present Urology Staff Surgeon, Department of Surgery
VAMC and Methodist Hospital,Clarian North, Clarian West,
Indianapolis, IN
OTHER APPOINTMENTS AND PROFESSIONAL CONSULTANTSHIPS:
DirectGene, Inc., Founder, Scientific Advisory Board, Clinical and
Research Consultant (1998 –2003)
Advagen, Inc., Scientific Advisory Board (2003-2004)
Focus Surgery, Inc., HIFU Proctor, Clinical and Scientific
Consultant for SBIR Grant (2001-present)
Amgen, Inc., Prostate Cancer Advisory Board Meetings (2000-2001)
Pfizer Speaker Bureau (2002-Present)
AstraZeneca LP Prostate Cancer Lecture Bureau (2003-Present)
Endocare, Inc., Proctor Kidney Cryotherapy (2003-Present)
Intuitive Surgery, Proctor Laparoscopic Robotic Surgery (2004-Present)
GSK Speaker Bureau (2002 - Present)
AMS Proctor (2005-Present)
SPECIALTY BOARD STATUS:
Diplomate, National Board of Medical Examiners - Part I, II, III Completed 1991
Diplomate, American Board of Urology - Part I 1996, Part II 2002
Recertified - 2009
LICENSURE AND CERTIFICATION:
1991-Present New York State Medical License (In-Active)
1997-Present Virginia State Medical License ( Active)
1999-Present Indiana State Medical License (Active)
P&T Dossier CV 03/2010
Page
2
Thomas A. Gardner, M. D.
PROFESSIONAL ORGANIZATIONS:
American Urological Association - Associate Member
Young Urologist Committee –Member
North Central Section - Member
American Society of Gene Therapy - Member
Society of Basic Urologic Research - Member
Society of Laparoendoscopic Surgeons - Member
Hoosier Oncology Group (HOG) - Member
Eastern Cooperative Oncology Group (ECOG) - Member
American Medical Association - Member
American Association for the Advancement of Science - Member
Phi Delta Epsilon Medical Fraternity
American Medical Student Association
Alpha Epsilon Delta Pre-Medical Honor Society
HONORS AND AWARDS:
In Rank Intramural Award Total
In Rank Extramural Award Total
1982
1982-1986
1995
1996-1998
1996
1997
1998
1999
1999
2000
2000-2002
2002
2004
$2,500
$277,500
Reagents Scholarship-New York Board of Reagents
Board of Trustees Honor Scholarship-George Washington University
Andlinger Fellowship Award-The American Austrian Foundation
American Foundation of Urologic Disease Research Scholar Award
CaPCURE Research Award-Co-Investigator (PI-Chung, LWK)
CaPCURE Research Award
($100,000)
AUA Annual Essay Contest Co-First Prize in Research Category ($ 1,000)
CaPCURE Research Award
($100,000)
VICAL Best Abstract Award – 1999 Cancer Gene Therapy Meeting ($ 2,500)
CaPCURE Research Award
($100,000)
NY Academy of Medicine Edwin Beer Award
($ 75,000)
AUA Annual Best Video Award – Honorable Mention
Indiana University Trustee Teaching Award
($ 2,500)
TEACHING ASSIGNMENTS SINCE APPOINTMENT
Formal Course Instruction:
Medical Students
Course Number
X601
L700
P&T Dossier CV 03/2010
Course Information
Introductions to Clinical Medicine- II - Urology Section
Sophomore Lecture (100 students) Series in Urology
Role – Urology Section Director and Lecturer, I organize 4
lectures per year (2 hours), Write Exam Questions
Organize the Didactic Examination of Male Genitalia 4 X 4 hour
Sessions)
Urology Core Clerkship 1999-2002 Senior Students –
(Average 3-4 Senior Students Per Month) Prior to 2002 all senior
student were required to rotate through the urology service and
attend 4 one hour lectures every other week for a majority of the
Page
3
Thomas A. Gardner, M. D.
year. I would generally give one of the 4 lectures half of the
time.
L897
Urology Senior Elective (IU or Non-IU) (1- 4 senior students per
month from July to October). These students would rotate on the
urology service attend clinics and operative procedures.
L804
Urology Research Elective (1-2 students per year, spending time
in the research lab or clinical research project
S700
Surgical Core Rotation –
Director & Lecturer - Urology Surgical Subspecialty
2002 – Present All 3rd year students attend 3 hours of lectures, I
give 2 of the 3. Nine series of lectures are given for the year.
I also developed the lecture series and arranged the rotation
schedule for the student when urology became part of this
course. L700 and overlapped for one year with S700.
Graduate Student
Course Number
Course Information
J854 Spring 2004
Course Title: Hematopoiesis –
Lecture Title: Vaccine Trials for Urologic Cancer
Students: 8-12
Format: Lecture (1 hr) and Small Group Discussion (1.5 Hrs)
J828 Fall 2004
Course Title: Virology
Lecture Title: Adenovirus and Parvovirus
Students: 8-12
Format: Lecture (1 hr) and Small Group Discussion (1.5 Hrs)
J802
Course Title: Microbiology and Immunology Summer Research
Rotation. (1 to 2 Graduate students pending 1 month in the lab.)
2002 Philip Abosh
2003 Juan Jimenez and
Student Mentoring:
Formal
Phillip Abosh
2002 – Present Ph.D Committee – Member
Juan Jimenez
2004 – Present Ph.D. Advisor and Mentor for F31-CA106215-01
Joseph Klink
2004 – Academic Advisor – Interested in Urology
Informal
I have mentored Medical Students, Residents and Fellows throughout my career at IU.
T. Shirakawa, MD, PhD 1998-9 at UVA, now at Kobe University as Assistant Prof.
M. Moghaddam, MD 2000-2002, now Assistant Professor in Iran
A Mosharafa, M.D. 2003-2004 now Assistant Professor in Epypt
SP Raikwar, Ph.D
2002-2005 now Assistant Scientist ,Univ. of Wisconsin
JA Jiménez
2002-Present MD/PhD Student (PhD Advisor)
M Mellon
2006-2008
P&T Dossier CV 03/2010
Page
4
Thomas A. Gardner, M. D.
CME Courses Taught
2000 Mini Medical School - Gene Therapy and Prostate Cancer
Location: University Place
Sponsor Dean’s Office
CME Course Title: “The 8Th Annual Family Practice Update
Date: June 1, 2002
Location: University Place Conference Center
Sponsor: Indiana University, School of Medicine, Division of CME
Title “Prostate Disorders, Diagnosis and Treatment”
CME Course Title: “Sexual Health Hospital Symposia” –Half-Day CME Program
Date: September 27, 2003
Location: Indiana University Medical Center
Sponsor: Boston University School of Medicine and National Foundation for Sexual
Health Medicine
Title: “Low Testosterone and Your Male Patients: Correlates, Symptoms and
Treatments”
CME Course Title: “Men’s Health Issues Update”- Half Day CME Program
Date: March 19, 2004
Location: University Place Conference Center
Sponsor: Indiana University, School of Medicine, Division of CME
Title: “Benign Prostatic Hypertrophy: Update on Diagnoses and Medical Management”
CME Course Title: “Latest Develop in Urology for Primary Care Physicians”,
Date: April 24, 2004
Location: Marriot Kingsgate Conference Center
Sponsor: Lecture Titles “Latest Advances in Diagnosing and Treating Erectile
Dysfunction” And “Case Study: ED and Men’s Sexual Health: Importance of Asking”
CME Lecture Title: “Erectile Dysfunction 2004 Update”
Date: June 24, 2004
Location: Indian Palace, Indianapolis, IN University Place Conference Center
Sponsor: VAMC, Division of CME
CME Lecture Title: “Kidney Masses: Evaluation and Treatment”
Date November 12, 2004
Location: Holiday Inn Conf Center
Sponsor: Urology Nursing Society Inc.
CME Lecture Titles: “2004 Treatment for Metastatic Prostate Cancer”, “HIFU and
Cryotyherpy for Prostate Cancer” and “Gene Therapy for Prostate Cancer”
Date: September 23, 2004
Location: University of Minnesota, Center for Prostate Cancer Symposium
CME Lecture Titles: “2009 Prostate Cancer Update"
Date: July 21, 2009
Location: Union Hospital, Evansville IN
P&T Dossier CV 03/2010
Page
5
Thomas A. Gardner, M. D.
Clinical Teaching
Clinical instruction of medical students, residents and fellows is conducted during my
clinical activities at University Hospital, Wishard and VA Medical Center. In 1999 2001 a majority of my clinical teaching occurred at Wishard Memorial Hospital at which
time I almost independently supported the clinical activities of the Urology Service. From
2002 until present I spend 1.5 days seeing patients in the clinic and 2.5 days in the
operating room.
PROFESSIONAL SERVICE:
(1) Service to the discipline
(a) State and Regional,
Public Service Announcements, Prostate Cancer
TV (Channel 13, RTV6, Health Beat)
Radio (Sound of Medicine)
CME and non-CME Lectures thought the State and Region
(b) National and international [list public offices, committees, organizations];
National Grant Reviews
2001 - DOD – CDMRP Prostate Cancer Research Program (PCRP)
2002 - DOD – CDMRP (PCRP) – Molecular Biology and Genetics
2002 - DOD – CDMRP (PCRP) – Consortium Award
2003 – NIH/NCI - R 03-124 NIAID
2005 - DOD – CDMRP (PCRP) – Clinical Trials Award
2006- DOD- CDMRP (PCRP)-Clinical & Experimental Therapeutics-1
International Grant Review
2002 - Canadian Institutes of Health Research – External reviewer
2003 – Fonds zur Frderung der wissenschaftlichen Forschung (FWF)
Austrian Science Fund- External Reviewer
International Consultant
Korea University - Gene Therapy Research Program
Kobe University - Gene Therapy Research Program
(2) service to patients/clients and related clinical institutions;
1.
“Phase I Study of Ad-OC-TK Plus Valacyclovir for the Treatment of Metastatic Recurrent
Prostate Cancer” Sponsor Investigator, Status Closed, PI Gardner, Co-PI Chung.
2.
“Clinical Investigation of High Intensity Focused Ultrasound (HIFU) For the Treatment of
Benign Prostatic Hyperplasia (BPH)” Sponsor FocusSurgery, Status Open (6/8/93), PI Gardner,
Co-PI: Birhle, Foster, Shalhav, Koch.
3.
“Cox II Inhibitors in the Treatment of Bladder Cancer” Sponsor NIH, Open (12/9/01) PIFoster, Co-PI: Bihrle, Gardner, Koch.
4.
“Phase III Randomized, Double- Blind Study of DFMO vs. Placebo In Low Grade superficial
Bladder Cancer” Sponsor ILEX Onc., Status Open (3/17/99) PI- Foster Co-PI: Bihrle, Gardner,
Koch, Mulcahy, Shalhav, Williams
5.
“The Selenium and Vitamin E Chemoprevention Trial(SELECT)” Sponsor NCI, Status
Open(7/2/01) PI Koch Co-PI: Foster, Gardner
6.
Feasibility Study for Organ Confined Prostate Cancer Treatment with HIFU Using
SONABLATE™ System Sponsor Focus Surgery, Status Open(7/25/01) PI – Koch; Co-PI: Gardner
7.
Feasibility Study for Locally Recurrent Prostate Cancer Treatment Using SONABLATE™
System Sponsor FocusSurgery, Status Open(5/14/01) PI – Koch; Co-PI: Gardner
P&T Dossier CV 03/2010
Page
6
Thomas A. Gardner, M. D.
8.
A Multicenter, Phase IIb, Four Arm, Dose Finding, Randomized, Placebo Controlled Study to
Determine The Long Term Prostate Cancer Chemoprevention Efficacy and Safety Of 20 mg, 40
mg, and 60 mg Daily of GTX-006 in Men with High Grade Prostate Intraepithelial Neoplasia (PIN)
Sponsor GTx; Status Open(7/2/01); PI- Koch; Co-PI: Bihrle, Foster, Gardner, Mulcahy
9.
A Randomized, Double Blind, Placebo Controlled Phase 3 Trial of Immunotherapy With
Autologous Antigen Presenting Cells Loaded With PA2024 (Provenge, AOC8015) in
Asymptomatic Subjects With Gleason Sum Less than or Equal to 7, Metastatic, Androgen
Independent Prostatic Adenocarcinomas. Sponsor Dendreon Corp. [D9902] PI Gardner
10. An Open Label, Single Arm Trial of Immunotherapy with Autologous Antigen Presenting
Cells Loaded with PA2024 (APC8015F) for Subjects with Objective Disease Progression and
Disease-Related Pain on Trial D9902 Part B PI: Thomas A. Gardner
11. A Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study of the Efficacy and
Safety of Dutasteride 0.5 mg Administered Once Daily for Four Years to Reduce the Risk of
Biopsy-Detectable Prostate Cancer. PI Thomas A. Gardner
12. A Randomized, Double-Blind, Placebo-Controlled Study of the Efficacy and Safety of
IC351(LY450190) Administered "On Demand" to Patients with Erectile Dysfunction Following
Bilateral Nerve-Sparing Radical Retropubic Prostatectomy, PROTOCOL H6D-MC-LVCI Sponsor
Lilly, Status Pending, PI Mulcahy, Co-PI: Gardner, Koch
Investigational New Drug/RAC Applications
1.
BB-IND 8115 - Adenovirus Vector (Ad-OC-TK, BioReliance) Expressing Thymidine Kinase
Gene Under Regulation of an Osteocalcin Promoter and Valacyclovir (PI Gardner TA)
2.
RAC #-276 - Phase I Study of Ad-OC-TK Plus Valacyclovir for the Treatment of Metastatic
Recurrent Prostate Cancer (PI Gardner TA)
3.
RAC #-426 - Phase I Study of Ad-OC-E1a for the Treatment of Metastatic Recurrent Prostate
Cancer (PI Gardner TA)
Patent(s)
1.
6,342,384 (1/29/02) Production of adenoviral vectors using serum-free suspension cell
culture in a hollow fiber system.
Patents Pending
1. MN - promoter based gene therapy for the treatment of malignancies.
2. ß-HCH promoter based gene therapy for testicular malignancies.
(3) Community service (Prostate Cancer Support Group Presentations)
(1) US TOO Charlottesville Chapter, Charlottesville, VA 4/97
(2) US TOO of the Valley, Waynesboro, VA 2/98
(3) Man-to-Man (ACS-Sponsored) Lynchburg Chapter, Lynchburg, VA 10/97
(4) US TOO Richmond Chapter, Richmond, VA 3/98
(5) US TOO Charlottesville Chapter, Charlottesville, VA 4/98
(6) Man-to-Man (ACS-Sponsored), Roanoke, VA 4/98
(7) US TOO Annual Regional Directors Meeting, Chicago, IL 10/98
(8) US TOO of the Valley, Waynesboro, VA 2/99
(9) US TOO Charlottesville Chapter, Charlottesville, VA 4/99
(10) Man-to-Man (ACS-Sponsored) Lynchburg Chapter, Lynchburg, VA 4/99
(11) US TOO Richmond Chapter, Richmond, VA 6/99
(12) Man-to-Man (ACS-Sponsored) – St. Vincent Hospital, Indianapolis, IN, 9/99
(13) Man-to-Man (ACS-Sponsored) – St. Vincent Hospital, Indianapolis, IN 1/00
(14) Man-to-Man (ACS-Sponsored) – St. Vincent Hospital, Indianapolis, IN 1/01
(15) Man-to-Man (ACS-Sponsored) – St. Vincent Hospital, Indianapolis, IN 1/02
P&T Dossier CV 03/2010
Page
7
Thomas A. Gardner, M. D.
(16)
(17)
(18)
(19)
(20)
Man-to-Man (ACS-Sponsored) – St. Vincent Hospital, Indianapolis, IN 1/03
Man-to-Man (ACS-Sponsored) – St. Vincent Hospital, Indianapolis, IN 1/04
Man-to-Man (ACS-Sponsored) – St. Vincent Hospital, Indianapolis, IN 1/05
Man-to-Man (ACS-Sponsored) – St. Vincent Hospital, Indianapolis, IN 1/06
Man-to-Man (ACS-Sponsored) – St. Vincent Hospital, Indianapolis, IN 1/07
P&T Dossier CV 03/2010
Page
8
Thomas A. Gardner, M. D.
UNIVERSITY SERVICE:
(1) university administrative service
Executive Council of Wishard Memorial Hospital - Member
Operating Room Committee Wishard Memorial Hospital - Member
IUMG-SC Wishard Specialty Group - Member
Urology Clinic Redesign Team of Wishard Memorial Hospital - Member
(2) university committee service
(a) departmental,
Walther Oncology Center, Member
Walther Oncology Center, Internal Advisory Board Member
(b) school,
NIH Cancer Center Scientific Review Committee (SRC) - Member
NIH GCRC Advisory Committee - Member
Institutional Review Board - Alternate Member
Indiana University Cancer Center – Member Experimental Therapeutics
IUCC Bone Cancer Working Group - Member
Clinical Research Strategic Planning Committee - Member
Radiation Oncology Chair Search Committee- Member
Cancer Center Director Search Commitee -Member
(c) campus,
Research III Strategic Planning Committee
(d) system [list name of committee, nature of participation, duration];
(3) student service [list student group, position/role, duration, formal-informal counseling
Not applicable
OTHER PROFESSIONAL ACTIVITIES:
Editorial Boards/ Journal Reviews
1997 – Reviewer - Journal of Urology
1997 – Reviewer – Investigative Urology
1998 – Editor - Gene Therapy and Molecular Biology
1999 – Editor - Tumor Targeting
2001 – Reviewer – Journal of Experimental Therapeutics
2001 – Reviewer – Molecular Therapy
2002 – Reviewer – Cancer Research
2002 – Reviewer - Urology
2002 – Reviewer – Cancer Research
Invited Presentations/Lectureships/Grand Rounds
1. Gardner TA, Li PS, Lopez M, Wright EJ, Goldstein M. Microsurgical
vasoepididymostomy: Which technique is best? The Department of Urology Grand Rounds,
General Hospital, Salzburg, Austria, February 1995.
2. Gardner TA, Kaneda Y, Liu D, Ko SC, Ginsberg RJ, Burt M, Kao C, Chung LWK. Gene
therapy for the treatment of sarcoma. Thoracic Service Grand Rounds-Department of SurgeryMemorial Sloan-Kettering Cancer Center, New York, NY, March 1998.
3. Gardner TA, Ko SC, Kao C, Shirakawa T, Cheon J, Gotoh A, Wu TT, Sikes RA, Zhau HE,
Cui Q, Balian G, Chung LWK. Exploiting stromal-epithial interaction for model development
and new strategies of gene therapy for prostate cancer and osteosarcoma metastases. International
Conference on Gene Therapy, Crete, Greece, August 1998.
4. Gardner TA, Ko SC, Kao C, Cheon J, Shirakawa T, Chung LWK. Tumor-restricted
adenoviral gene therapy applied to osteosarcoma and prostate cancer. Cold Spring Harbor
Laboratory’s Meeting on Vector targeting strategies for therapeutic gene delivery, March 1999.
P&T Dossier CV 03/2010
Page
9
Thomas A. Gardner, M. D.
5. Gardner TA, Ko SC, Kao C, Chung LWK. Ad-OC-TK gene therapy for the treatment of
metastatic osteosarcoma. Pediatric Oncology Service Grand Rounds-Department of MedicineMemorial Sloan-Kettering Cancer Center, New York, NY, June 1999.
6. Gardner TA. Gene therapy for the treatment of urologic malignancies. Clinical Science
Symposia at the 32nd Annual Meeting of American Society of Nephrology, Miami, FL,
November 1999.
7. Gardner TA. “High Intensity Focused Ultrasound for Localized and Recurrent Prostate
Cancer” Grand Rounds, Department of Urology, University of Michigan, August, 2000.
8. Gardner TA. “Results of a Phase I Trial of Ad-OC-TK/VAL for Metastatic and Recurrent
Prostate Cancer.” Prostate Cancer SPORE Lectureship, Department of Urology, University of
Michigan, August, 2000.
9. Gardner TA. Genetics underlying urologic malignancies. Fourth Uro-Oncology Conference,
Lake Louise, Alberta, Canada, February 24-28, 2001.
10. Gardner TA. “Basic gene therapy for the uro-oncologists”. Fourth Uro-Oncology
Conference, Lake Louise, Alberta, Canada, February 24-28, 2001.
11. Gardner TA. “Gene therapy approaches for metastatic prostate and kidney cancer.” Grand
Rounds, Dept. of Urology, New York Hospital-Cornell Medical Center, NY, March 21, 2001.
12. Gardner TA, “Gene Therapy for Osteosarcoma” CTEP sponsored “Biology of Childhood
Osteogenic Sarcoma and Potential Targets for Therapeutic Development. Bethesda MD, November
29-30, 2001.
13. Gardner TA, “Gene Therapy, What is it?” State of the Art lecture at NCS of AUA 2001
Chicago IL, January 17, 2002.
14. Gardner TA, “Chasing the Cash to Find the Cure” American Marketing Association, South
Bend IN, January 24, 2002.
15. Gardner TA, “Treatment Options for Advanced and Recurrent Prostate Cancer:Vaccines and
Thermal Therapy” Community Cancer Care Quarterly Seminars, April 29th, 2004.
16. Gardner TA, Visiting Professor – Prostate Cancer Symposium University of
Minnesota, September 23,2004
17. Gardner TA, “Gene Therapy, What is it?” State of the Art lecture at NCS of AUA 2004 ,
October 15, 2004.
Personal CME and non CME Clinical and Research Activity
2000 – 2004 325 hours Departmental and IU CME Credits
1999 – 2004 175 hours CME Credits from Meeting
New clinical techniques acquired and incorporated in to clinical practice
*Each of these techniques required formal training (online up to two day hands on courses) and
proctoring leading authority in the procedure.
1.
2.
3.
4.
5.
6.
7.
8.
9.
High Intensity Focused Ultrasound for Prostate
Advanced Laparoscopy
DaVinci Robotic Laparoscopy
Kidney Cryotherapy
Prostate Cryotherapy
Transurethral Microwave Thermal Therapy
Transurethral Needle Ablation of Prostate
Interstim Sacral Nerve Implantation
TVT, TOT, TVT-O Urethral Sling Procedures
P&T Dossier CV 03/2010
Page
10
Thomas A. Gardner, M. D.
GRANTS AND FELLOWSHIPS:
1999-2007 Intramural Direct Total
$155,000
1999-2007 Extramural Direct Total $1,225,000
1996-1998
1996-1998
1996-1997
1998
2000
2001
2000-2003
2000-2005
2002-2003
2002-2003
2003-2006
2005-2006
American Foundation of Urologic Disease Research Scholar Fellowship
NIH-Funded Training Program Cell and Molecular Biology of the
Urogenital System 5-T32-DK07642
(PI-Gardner TA, 32,300/yr)
ACS-Institutional Research Grant-Co-Investigator
(PI-Kao, C)
DOD DAMD17-98-1-8643 Co-Investigator (10%)
(PI-Kao, C)
IUCC Bone Cancer Pilot Grant
(PI Gardner TA, Direct $ 50,000)
IUCC Prostate Caner Pilot Grant
(PI Gardner TA, Direct $ 40,000)
DOD DAMD17-00-1-0027 New Investigator Award
(PI Gardner TA, Direct $225,000)
KO8 CA79544-01A2 Clinical Scientist Training Grant (PI Gardner TA, Direct $625,000)
Kidney Research and Tissue Storage (Larson Gift)
(PI Gardner TA, Direct $ 50,000)
IUCC Renal Cell Carcinoma Pilot Project
(PI Gardner TA, Direct $ 15,000)
DOD DAMD17-03-1-0077 New Idea Award
(PI Gardner TA, Direct $375,000)
DOD Clinical Trial Development Award
(PI Gardner TA, Direct $100,000)
Funding Active Funding
(1) Grant # DAMD17-00-1-0027
Funding Period11/15/99-11/14/02
Role PI
Title “Tumor restricted gene therapy for metastatic prostate cancer”
The objective of this grant is to test the hypothesis that a tissue specific oncolytic vector
can eradicate human prostate cancer growing in an established metastatic animal model.
There is no overlap of the specific aims between this grant and the proposed grant. The
grants share several techniques including the animal model and adenoviral production.
(2) Grant # NIH/NCI - 1R01 CA80825-01A2
12/1/00-5/31/03
Role Co-Investigator
Title “Tissue-specific gene therapy of pulmonary
metastasis”
The objective of this proposal is to study the ability of locoregional delivery and tissuespecific promoter to target osteosarcoma in a metastatic rat model.
(3) Grant # 2987536
Funding Period 5/1/02 – 4/30/03
Renal Cell Carcinoma Pilot Project
(Direct $ 15,000)
Role PI
Title: “ MN promoter Activity in Renal Cell Carcinoma”
The objective of this pilot project was to generate preliminary data to allow for a R01
submission in tumor specific oncolysis of renal cell carcinoma.
(4) Grant # NIH/NCI 1R01 CA80825-01A2 Funding Period 12/1/00-5/31/02
Role Co-investigator PI C Kao
Direct Costs 849,850
Title: “Tissue-specific gene therapy of pulmonary metastasis”
The objective of this proposal is to study the ability of locoregional delivery and tissuespecific promoter to target osteosarcoma in a metastatic rat model.
(5) Grant # NIH 2 R44 CA83244-02:
Funding Period11/2000-02/2004
Role : Consultant
Direct $3000/year, 2 years
Title "Quantitative Imaging & Treatment with Focused Ultrasound," (Phase II SBIR)
The objective of this proposal is to quantify the temperatures associated high intensity focused
ultrasound.
(6) Grant # NIH 2 R44 CA81340-02A2:
Role: Consultant
P&T Dossier CV 03/2010
Page
11
Funding Period 5/2002-4/2004
Direct $5000
Thomas A. Gardner, M. D.
Title "High Intensity Ultrasound for Prostate Treatment" (Phase II SBIR)
The object of this proposal was to test a phased array transducer with Doppler capabilities.
(7) Indiana ICMIC Planning Grant
Funding Period 6/7/02 – 4/30/03
Role: PI
Direct $36,116.77 (Acct #4688405)
Title: “Micro-PET imaging of TK based gene therapy in Prostate cancer models”
The object of this proposal was to non-invasively quantify the tumor burden in animal
models of prostate cancer before and after application of gene therapy.
(8) George M. O’Brien Center for Advanced Renal Microscopic
Analysis, (PI Dr. Bruce A. Molitoris)
Funding Period 2002 -2004
Role Co-Investigator (PI Raikwar S)
Direct $42,000 (Acct #’s 4688630, 4688699)
Title: Pilot Project 3 “Delineation of tumor vascular in response to anti-angiogenic gene
therapy”
The object of this proposal was to quantify the alteration in tumor vasculature in animal
models of prostate cancer before and after application of gene therapy.
(9) Grant # NIH KO8 CA79544-01A2
Funding Period: 7/01/00-6/30/05
Role PI
Title “Locoregional gene therapy for cancer metastases”
The objective of this grant is to test the hypothesis that a tissue specific and targeted toxic
gene therapy can be safely and effectively delivered via locoregional perfusion to animals
with human metastatic renal cell carcinoma and prostate cancer. There is no overlap of
the specific aims between this grant and other support. The other support listed share
several techniques including the animal model and adenoviral production.
(10) Grant # DAMD17-03-1-0077
Funding Period: 5/1/03 – 4/30/06
Role: PI Title “Development and Pre-clinical evaluation of a novel ProstateRestricted Replication Competent Adenovirus-Ad-IU-1”
The major goal of this proposal is to combine TK gene therapy and MicroPet imaging
with replication competent adenovirus to target prostate cancer.
(11) Grant # NIH 2 R44 DK059664-02A1:
Funding Period: 6/2003-5/2005
Role: Consultant $5000/year Title: "Ultrasound Imaging and Therapy for
Prostate Cancer," (Phase II SBIR)
The major goal of this investigation is to further advance a HIFU device for prostate
treatment using canine models.
(12) Glaxo Smith Kline, AR140006
10/29/03 – 07/23/09
Role Institutioal PI Funding Support $247,380 Direct
$61,470 Indirect
Title :“A Randomized, Double-Blind, Placebo Controlled, Parallel Group Study of the
Efficacy and Safety of Dutasteride 0.5mg Administered Orally Once Daily for Four Years
to Reduce the Risk of Biopsy-Detectable Prostate Cancer”.
(13) Dendreon Corporation,
10/02/03 – Current
Title :“A Randomized, Double Blind, Placebo Controlled, Phase 3 Trial of Immunotherapy
with Autologous Antigen Presenting Cells Loaded with PA2024… and An Open Label
Single Arm Trial of Immunotherapy with Autologous Antigen Presenting Cells… PB01”.
Funding Support
$36,918 Direct
$8,855 Indirect
P&T Dossier CV 03/2010
Page
12
Thomas A. Gardner, M. D.
PUBLICATIONS (Refereed):
**All Publications should be considered an integration of research scholarship and professional
service.
(*Corresponding Authorship, #Equal First Authorship)
1. Gardner TA, Poppas DP, Wei JT, Blavias JG: Volvulus of the ileal conduit: A late complication. J.
Urol. 152:948-950, 1994.
2. Ngadiman S, Hoda SA, Campbell WG Jr, Gardner TA, May M: Concurrent malakoplakia and primary
squamous cell carcinoma arising in long standing chronic cystitis. Brit. J. Urol. 74:801-802, 1994.
3. Matthews GJ, Gardner TA, Eid JF: In vitro fertilization with intracytoplasmic sperm injection(ICSI)
improves pregnancy rates for electroejaculated sperm. J. Urol. 155:1934-1937, 1996.
4. Gardner TA, Boyd S, Theodorescu D. Factors predicting hospital length of stay in patients treated by
radical prostatectomy. Surg. Forum 48: 597-600, 1997.
5. Cheon J, Ko S-C, Gardner TA, Shirakawa T, Kao C, Chung LWK. Osteosarcoma: Osteocalcin
promoter based suicide gene therapy in combination with methotrexate in a murine osteosarcoma
model. Cancer Gene Therapy 4(5): 359-365, 1997.
6. Gotoh A, Ko SC, Shirakawa T, Cheon J, Kao C, Miyamoto T, Gardner TA, Ho LJ, Cleutjens C,
Trapman J, Graham FL, Chung LWK. Development of prostate-specific antigen promoter-based gene
therapy for androgen-independent human prostate cancer. J Urol 160: 220-229, 1998.
7. Gardner TA, Lemer ML, Schlegel PN, Waldbaum RS, Vaughan ED Jr., Steckel J. Microfocal prostate
cancer: Biopsy cancer volume does not predict actual tumor volume. Brit J Urol 81(6):839-43, 1998.
8. Gardner TA, Ostad M, Mininberg DT. Diagnostic flexible peritoneoscopy: Assessment of the
contralateral internal ring during unilateral herniorrhaphy. J Pediatr Surg 33(10): 1486-9, 1998.
9. Shirakawa T, Ko SC, Gardner TA#, Cheon J, Miyamoto T, Gotoh A, Chung LWK, Kao C. In vivo
suppression of osteosarcoma pulmonary metastasis with intravenous osteocalcin promoter-based toxic
gene therapy. Cancer Gene Therapy 5(5): 274-280, 1998.
10. Pavlovich CP, Gmyrek GA, Gardner TA, Poppas DP, Mininberg DT. Flexible transinguinal laparoscopy
to assess the contralateral ring in pediatric inguinal hernias. Tech Urol 4(3): 141-4, 1998.
11. Shirakawa T, Gardner TA*, Ko SC, Bander N, Woo S, Gotoh A, Kamidono S, Chung LWK, Kao C.
Cytotoxicity of Adenoviral-Mediated Cytosine Deaminase Plus 5-Fluorocytosine Gene Therapy is
Superior to Thymidine Kinase Plus Acyclovir in a Human Renal Cell Carcinoma Model. J Urol 162:94954, 1999.
12. Shirakawa, T.; Gotoh, A.; Wada, Y.; Kamidono, S.; Ko, S. C.; Kao, C.; Gardner, T. A.;
Chung, L. W.Tissue-specific promoters in gene therapy for the treatment of prostate cancer
Mol Urol 4(2) 73-82, 2000 (summer)
13. R. Seip, M. Biswas, M. Kuznetsov, T. Gardner, and N. Sanghvi, "Transurethral High
Intensity Focused Ultrasound: Catheter Prototypes and Experimental Results," IEEE
Ultrasonics Symposium Proceedings, Vol. 2, 2000, pp. 1413-1416.
14. Shirakawa T, Gotoh, A, Gardner TA, Kao C, Zhang Z-J, Matsubara S, Wada Y, Hinata N, Fujisawa M,
Hanioka K, Matsuo M, Kamidono S. P53 Adenoviral vector (Ad-Cmv-P53) induced prostatic growth
inhibition of primary cultures of human prostate and an experimental rat model. J Gene Medicine
2:426-432, 2000.
15. Gardner TA, Bissonette EA, Petroni GR, McClain R, Sokoloff MH, and Theodorescu D. Surgical and
postoperative factors affecting length of hospital stay after radical prostatectomy. Cancer 89:424-30,
2000.
16. Koeneman KS, Kao C, Ko SC, Yang L, Wada Y, Kallmes DF, Gillenwater JY, Zhau HE, Chung LWK,
Gardner TA. Osteocalcin-directed gene therapy for prostate-cancer bone metastasis. World J Urol
18(2):102-10, 2000.
17. Gardner TA, Ko S-C, Yang L, Cadwell JJS, Chung LWK, Kao C. Serum-free recombinant production of
adenoviral using a hollow fiber capillary system. Biotechniques 30:422-427, 2001.
18. Soergel TM, Koch MO, Foster RS, Bihrle R, Wahle G, Gardner TA, Jung SH. Accuracy of predicting
long-term prostate specific antigen outcome based on early prostate specific antigen recurrence results
after radical prostatectomy, J Urol, 166(6), 2198, 2001.
P&T Dossier CV 03/2010
Page
13
Thomas A. Gardner, M. D.
19. Shirakawa T, Sasaki R, Gardner TA, Kao C, Zhang ZJ, Sugimura K, Matsuo M, Kamidono S, Gotoh A.
Drug-resistant human bladder-cancer cells are more sensitive to adenovirus-mediated wild-type p53
gene therapy compared to drug-sensitive cells, Int J Cancer, 94(2), 282-289, 2001.
20. Matsubara S, Wada Y, Gardner TA, Egawa M, Park MS, Hsieh CL, Zhau HE, Kao C, Kamidono S,
Gillenwater JY, Chung LWK. A conditional replication-competent adenoviral vector, Ad-OC-E1a, to cotarget prostate cancer and bone stroma in an experimental model of androgen-independent prostate
cancer bone metastasis, Cancer Res, 61(16): 6012 - 6019, 2001.
21. Cheon J, Moon DG, Cho HY, Park HS, Kim JJ, Gardner TA, Kao C. Adenovirus –mediated suicide
gene therapy in an orthotopic murine bladder tumor model. Int J Urol 9(5):29-36, 2002.
22. Siqueira, T. M., Jr., Kuo, R. L., Gardner, T. A., Paterson, R. F.Stevens, L. H., Lingeman, J. E., Koch, M.
O., Shalhav, A. L. Major complications in 213 laparoscopic nephrectomy cases: the Indianapolis
experience. J Urol 168(4 OCT):1361-5, 2002
23. Siqueira, T. M., Jr., Gardner, T. A., Kuo, R. L., Paterson, R. F., Stevens, L. H., Lingeman, J. E.,
Shalhav, A. L.. One versus two proficient laparoscopic surgeons for laparoscopic live donor
nephrectomy. Urology 60(3 SEP) 406-9, discussion 409-10, 2002
24. R. Seip, J. Tavakkoli, R. Carlson, A. Wunderlich, N. Sanghvi, K. Dines, and T. Gardner, "High-Intensity
Focused Ultrasound (HIFU) Multiple Lesion Imaging: Comparison of Detection Algorithms for RealTime Treatment Control," IEEE Ultrasonics Symposium Proceedings, 2002, pp. 1395-1398.
25. Shalhav, A. L., Siqueira, T. M., Jr., Gardner, T. A., Paterson, R. F., Stevens, L. H. Manual specimen
retrieval without a pneumoperitoneum preserving device for laparoscopic live donor nephrectomy., J
Urol 168(3 SEP):941-4, 2002.
26. Shalhav, A. L., Barret, E., Lifshitz, D. A., Stevens, L. H., Gardner, T. A., Lingeman, J. E.
Transperitoneal laparoscopic renal surgery using blunt 12-mm trocar without fascial closure. J Endourol
16(1 FEB): 43-6, 2002
27. Uchida T, Sanghvi NT, Gardner TA, Koch MO, Ishii D, Minei S, Satoh T, Hyodo T, Irie A, Baba S.
Transrectal high intensity focused ultrasound for theatment of patients with stage T1b-2N0M0 localized
prostate cancer: A preliminary report. Urology 59(3):394-399, 2002.
28. Zhang S, Gu J, Yang N-S, Kao C, Gardner TA, Eble JN, Cheng L. Relative promoter strengths in four
human prostate cancer cell lines evaluated by particle bombardment-mediated gene transfer. Prostate
51:286-292, 2002.
29. Zhang S, Zeng G, Kao C, Gardner TA, Sweeney C, Yang N-S, Eble JN, Cheng L. Fas-Fas ligand
signaling pathway mediates an interleukin-12-induced rejection of murine prostate tumor system.
Prostate 52:1-8, 2002.
30. Jiang J, Ulbright TM, Zhang S, Eckert GJ, Kao C, Gardner TA, Koch MO, Eble JN, Cheng L. Fas and
Fas ligand expression is elevated in prostatic intraepithelial neoplasia and prostatic adenocarcinoma.
Cancer 95(2):296-300, 2002.
31. Gardner TA#, Sloan J, Raikwar SP, Kao C, Prostate cancer Gene Therapy Past experiences
and Future Promise, Cancer and Metastasis Reviews 21:137-145, 2002.
32. Hong H, Koch MO, Foster RS, Bihrle R, Gardner TA, Fyffe J, Ulbright TM, Eble JN, Cheng L.
Anatomical distribution of periprostatic adipose tissue: A mapping study of 100 radical prostatectomy
specimens. Cancer (In Press), 2003.
33. Kubo, H, TA Gardner#, Y Wada, KS Koeneman, A Gotoh, L Yang, C Kao, SD Lim, MB
Amin, H Yang, ME Black, S Matsubara, M Naqkagawa, JY Gillenwater, HE Zhau, LW
Chung. Phase I dose escalation clinical trial of adenovirus vector carrying osteocalcin
promoter-driven herpes simplex virus thymidine kinase in localized and metastatic hormonerefractory prostate cancer. Hum, Gene Therapy 14:227-241, 2003.
34. Lee, S-J, K Lee, X Yang, C Jung, TA Gardner, H-S Kim, M-H Jeng, C Kao. NFATc1 with
AP-3 site binding specificity mediates gene expression of prostate-specific-membraneantrigen. J Mol. Biol. 330:749-760, 2003.
35. Zeng, G, Z Hu, MS Kinch, DA Flockhart, C Kao, TA Gardner, S Zhang, L Li, LA, Koch MO
Baldridge, TM Ulbright, JN Eble, L Cheng. High Level Expression of EphA2 Receptor
Tyrosine Kinase in Prostatic Intraepithelial Neoplasia. Am. J Pathol. 163:2271-2276, 2003.
P&T Dossier CV 03/2010
Page
14
Thomas A. Gardner, M. D.
36. Gorlick, R., Anderson, P., Andrulis, I.,Arndt, C.,Beardsley, G. P.,Bernstein, M.,Bridge, J.,
Cheung, N. K., Dome, J. S., Ebb, D. Gardner, T.A, Gebhardt, M., Grier, H., Hansen, M.,
Healey, J.Helman, L., Hock, J., Houghton, J., Houghton, P., Huvos, A., Khanna, C., Kieran,
M.Kleinerman, E., Ladanyi, M., Lau, C., Malkin, D., Marina, N., Meltzer, P., Meyers, P.,
Schofield, D., Schwartz, C., Smith, M. A., Toretsky, J., Tsokos, M., Wexler, L., Wigginton,
J.Withrow, S., Schoenfeldt, M., Anderson, B. Biology of childhood osteogenic sarcoma and
potential targets for therapeutic development: meeting summary. Clin Cancer Res 9(15
NOV):5442-53
37. Hong, H., Koch, M. O., Foster, R. S., Bihrle, R., Gardner, T. A., Fyffe, J., Ulbright, T. M.,
Eble, J. N., and Cheng, L. Anatomic distribution of periprostatic adipose tissue: a mapping
study of 100 radical prostatectomy specimens. Cancer, 97: 1639-1643, 2003.
38. Brandli, D. W., Koch, M. O., Foster, R. S., Bihrle, R., and Gardner, T. A. Biochemical
disease-free survival in patients with a high prostate-specific antigen level (20-100 ng/mL)
and clinically localized prostate cancer after radical prostatectomy. BJU Int, 92: 19-22;
discussion 22-13, 2003.
39. Koch, M. O., Nayee, A. H., Sloan, J., Gardner, T., Wahle, G. R., Bihrle, R., and Foster, R. S.
Early catheter removal after radical retropubic prostatectomy: long-term followup. J Urol,
169: 2170-2172, 2003.
40. Paterson, R. F., Barret, E., Siqueira, T. M., Jr., Gardner, T. A., Tavakkoli, J., Rao, V. V.,
Sanghvi, N. T., Cheng, L., and Shalhav, A. L. Laparoscopic partial kidney ablation with high
intensity focused ultrasound. J Urol, 169: 347-351, 2003.
41. Mosharafa, A., Koch, M., Shalhav, A., Gardner, T., Logan, T., Bihrle, R., and Foster, R.
Nephrectomy for metastatic renal cell carcinoma: Indiana University experience. Urology,
62: 636-640, 2003.
42. Chung, L. W., Hsieh, C. L., Law, A., Sung, S. Y., Gardner, T. A., Egawa, M., Matsubara, S.,
and Zhau, H. E. New targets for therapy in prostate cancer: modulation of stromal-epithelial
interactions. Urology, 62: 44-54, 2003.
43. Hsieh, C. L., Gardner, T. A., Miao, L., Balian, G., and Chung, L. W. Cotargeting tumor and
stroma in a novel chimeric tumor model involving the growth of both human prostate cancer
and bone stromal cells. Cancer Gene Ther, 11(2 FEB): 148-155, 2004.
44. Cheng, L, GT MacLennan, C Pan, TD Jones, S Zhang, CR Moore, J Gu, C Kao, TA
Gardner. Allelic loss of the active X chromosome during bladder carcinogenesis. Arch
Pathol Lab Med. 128(2 FEB):187-190, 2004.
45. Zheng, Q-H, J-Q Wang, X Liu, X Fei, BH Mock, BE Glick-Wilson, ML Sullivan, SP Raikwar,
TA Gardner, C Kao, GD Hutchins. An improved total synthesis of PET HSV-tk gene reporter
probe 9-(4-[18F]fluoro-3-hydroxymethylbutyl)guanine ([18F]FHBG). Syn. Commun. 34:671685, 2004.
46. Shirakawa, T., Gotoh, A., Zhang, Z., Kao, C. , Chung, L. W., Gardner, T. A.. Development
of human chorionic gonadotropin subunit-beta promoter-based toxic gene therapy for
testicular cancer. Urol 63(3 MAR):613-18, 2004
47. Q-H. Zheng, T.A. Gardner, S.P. Raikwar, C. Kao, K.L. Stone, T.D. Martinez, B.H. Mock, X.
Fei, J-Q. Wang, G.D. Hutchins: [11C]Choline as a PET biomarker for assessment of prostate
cancer tumor models. Bioorg. Med. Chem. 2004, 12(11), 2887-2893.
48. Hong H, Kao C, Jeng M, Eble JN, Koch MO, Gardner TA, Zhang S, Li L, Pan C, Hu Z,
MacLennan GT, Cheng L:Aberrant expression of CARM1, a transcriptional coactivator of
androgen receptor, in the development prostate cancer and androgen-independent status.
Cancer 101:83-89, 2004.
49. Sweeney C, Li L, Shanmugam R, Bhat-Nakshatri P, Jayaprakasan V, Baldridge LA,
Gardner TA, Smith M, Nakshatri H, Cheng L. Nuclear Factor Kappa B is Constitutively
Activated in Prostate Cancer In Vitro and is Over-expressed in Prostatic Intra-epithelial
Neoplasia and Adenocarcinoma of the Prostate. Clinical Cancer Research 10(16):5501-7
2004(AUG)
P&T Dossier CV 03/2010
Page
15
Thomas A. Gardner, M. D.
50. Sundaram CP, Koch MO, Gardner TA, Bernie JE (2005). "Utility of the fourth arm to
facilitate robot-assisted laparoscopic radical prostatectomy." BJU Int 95(1): 183-6.(JAN)
51. Wang, JQ, Fei X, Gardner TA, Hutchins GD, Zheng QH (2005). "Synthesis of 2-amino-6-(4[11C]methoxyphenylthio)-9-[2-(phosphonomethoxy)ethyl]purine bis(2,2,2-trifluoroethyl) ester
as a novel potential PET gene reporter probe for HBV and HSV-tk in cancers." Bioorg Med
Chem 13(2): 549-56. (JAN)
52. Ou YC, Gardner TA, Kao C, Zhau HE, Chung LWK. (2005). "A potential for tissue restrictive
gene therapy in renal cell carcinoma using MN/CA IX promoter." Anticancer Res 25(2A):
881-6.(MAR)
53. Li X, Zhang YP, Kim HS, Bae KH, Stantz, KM, Lee, SJ, Jung C, Jimenez JA, Gardner TA,
Jeng MH, Kao C. (2005). "Gene therapy for prostate cancer by controlling adenovirus E1a
and E4 gene expression with PSES enhancer." Cancer Res 65(5): 1941-51. (MAR)
54. Cheng L, Koch MO, Juliar BE, Daggy JK, Foster RS, Bihrle R, Gardner TA. (2005). "The
combined percentage of Gleason patterns 4 and 5 is the best predictor of cancer
progression after radical prostatectomy." J Clin Oncol 23(13): 2911-7. (MAY)
55. Jung C, Kim RS, Zhang H, Lee SJ, Sheng H, Loehrer PJ, Gardner TA, Jeng MH, Kao C.
(2005). "HOXB13 is downregulated in colorectal cancer to confer TCF4-mediated
transactivation." Br J Cancer 92(12): 2233-9. (JUN)
56. Koch MO, Gardner TA (2005). "Thermal-based treatment options for localized prostate
cancer." Curr Treat Options Oncol 6(5): 379-87. (JUN)
57. Armatys S, Koch MO, Bihrle R, Gardner TA, Cheng L: Is it necessary to separate clinical
stage T1c from T2 prostate adenocarcinoma? BJU Int 96: 777-780, 2005.(OCT)
58. Malaeb BS, Gardner TA, Margulis V, Yang L, Gillenwater JY, Chung LWK, Macik G,
Koeneman KS. (2005). "Elevated activated partial thromboplastin time during administration
of first-generation adenoviral vectors for gene therapy for prostate cancer: identification of
lupus anticoagulants." Urology 66(4): 830-4.(OCT)
59. Armatys SA, Cheng L, Gardner TA, Sundaram CP (2005). "Pulmonary sequestration
presenting as retroperitoneal cyst: case report." J Endourol 19(8): 997-9. (OCT)
60. Bernie JE, Venkatesh R, Bargman V, Gardner TA, Cheng L, Sundaram CP. (2005).
"Comparison of laparoscopic pyeloplasty with and without robotic assistance." Jsls 9(3):
258-61.(NOV)
61. Bernie JE, Ng J, Bargman V, Gardner TA, Cheng L, Sundaram C P(2005)."Evaluation of
hydrogel tissue sealant in porcine laparoscopic partial-nephrectomy model." J Endourol
19(9): 1122-6. (NOV)
62. Li X, Zhang J, Gao H, Vieth E, Bae KH, Zhang YP, Lee SJ, Raikwar S, Gardner TA,
Hutchins GD, VanderPutten D,Kao C, Jeng MH (2005). "Transcriptional targeting modalities
in breast cancer gene therapy using adenovirus vectors controlled by alpha-lactalbumin
promoter." Mol Cancer Ther 4(12): 1850-9.(DEC)
63. Raikwar SP, Temm CJ, Raikwar NS, Kao C, Molitoris BA, Gardner TA. (2005). "Adenoviral
vectors expressing human endostatin-angiostatin and soluble Tie2: enhanced suppression
of tumor growth and antiangiogenic effects in a prostate tumor model." Mol Ther 12(6):
1091-100. (DEC)
64. Gardner TA, Koch MO. (2005). "Prostate cancer therapy with high-intensity focused
ultrasound." Clin Genitourin Cancer 4(3): 187-92. (DEC)
65. Li X, Raikwar SP, Liu YH, Lee SJ, Zhang YP, Zhang S, Cheng L, Lee SD, Juliar BE,
Gardner TA, Jeng MH, Kao C. (2006). "Combination therapy of androgen-independent
prostate cancer using a prostate restricted replicative adenovirus and a replication-defective
adenovirus encoding human endostatin-angiostatin fusion gene." Mol Cancer Ther 5(3):
676-84. (MAR)
66. Jimenez JA, Kao C, Raikwar S, Gardner TA. (2006). "Current status of anti-angiogenesis
therapy for prostate cancer." Urol Oncol 24(3): 260-8.(MAY)
P&T Dossier CV 03/2010
Page
16
Thomas A. Gardner, M. D.
67. Desai P, Jimenez JA, Kao C, Gardner TA. (2006). "Future innovations in treating advanced
prostate cancer." Urol Clin North Am 33(2): 247-72, viii.(MAY)
68. Li X, Jung C, Liu YH, Bae KH, Zhang YP, Zhang HJ, Vanderputten D, Jeng MH, Gardner
TA, Kao C. (2006). "Anti-tumor efficacy of a transcriptional replication-competent
adenovirus, Ad-OC-E1a, for osteosarcoma pulmonary metastasis." J Gene Med 8(6): 67989. (JUN)
69. Li X, Liu YH, Zhang YP, Zhang S, Pu X, Gardner TA, Jeng MH, Kao C (2007). Fas ligand delivery by
a prostate-restricted replicative adenovirus enhances safety and antitumor efficacy. Clin Cancer Res
13(18): 5463-73.
70. Mellon MJ, Ahn M, Jimenez JA, Kao C, Gardner TA. (2008) Anti-angiogenic gene
therapy for metastatic renal cell carcinoma produces tumor growth suppression in an
athymic nude mouse model. J Urol 179(2): 737-42. J Urol. 2008 Feb;179(2):737-42.
Epub 2007 Dec 20.
71. Li X, Liu YH, Lee SJ, Gardner TA, Jeng MH, Kao C (2008). Prostate restricted replicative adenovirus
expressing human endostatin-angiostatin fusion gene exhibiting dramatic antitumor efficacy. Clin
Cancer Res 14(1): 291-9.
72. Mellon MJ, Bae KH, Jimenez JA, Kao C, Gardner TA (2008). Suppression of renal cell carcinoma
growth and metastasis with sustained antiangiogenic gene therapy. Hum Gene Ther. 2008
May;19(5):487-95.
73. Ahn M, .Lee, S. J.Li, X.Jimenez, J. A.Zhang, Y. P.Bae, K. H.Mohammadi, Y.Kao,
C.Gardner, T. AEnhanced combined tumor-specific oncolysis and suicide gene
therapy for prostate cancer using M6 promoterCancer Gene Ther. 2009
Jan;16(1):73-82. Epub 2008 Sep 5.
74. Gardner, T. A.Lee, S. J.Lee, S. D.Li, X.Shirakawa, T.Kwon, D. D.Park, R. Y.Ahn, K.
Y.Jung, C. Differential expression of osteocalcin during the metastatic progression of
prostate cancer. Oncol Rep. 2009 Apr;21(4):903-8.
75. Gardner TA, Logan T. Prognostic implications of polymorphisms and interleukin-2
therapy for renal cell carcinoma. J Urol. 2009 Aug;182(2):425-6. Epub 2009 Jun 13.
76. Jimenez JA, Li X, Zhang YP, Bae KH, Mohammadi Y, Pandya P, Kao C, Gardner TA.
Antitumor activity of Ad-IU2, a prostate-specific replication-competent adenovirus encoding
the apoptosis inducer, TRAIL. Cancer Gene Therapy epub date 2009/10/03
77. Bahler CD, Foster RS, Bihrle R, Beck SD, Gardner TA, Sundaram CP, Masterson TA,
Cheng L, Koch MO. Radical prostatectomy as initial monotherapy for patients with
pathologically confirmed high-grade prostate cancer. BJU Int. 2009 Oct 26
P&T Dossier CV 03/2010
Page
17
Thomas A. Gardner, M. D.
78. Invited Book Chapters, Articles and Reviews (Peer-invited and Non-Peer Reviewed)
1. Young GPH, Li PS, Gardner TA, Goldstein M: Animal models for microsurgical training and
research, Chapter 33, In Surgery of Male Infertility, Marc Goldstein (ed.), 1994.
2. Goldstein M, Li PS, Gardner TA: Urologic microsurgery: Training and research, Course Manual, The
AUA surgical learning center meeting, Microsurgery, Houston, Texas, 1994.
3. Gardner TA, Theodorescu D. Diagnosis and treatment of prostate cancer. Surg. Sci. Management
3(12): 20-28, 1997
4. Gardner TA, Ko SC, Kao C, Shirakawa T, Cheon J, Gotoh A, Wu TT, Sikes RA, Zhau HE, Cui Q,
Balian G, Chung LWK. Exploiting stromal-epithelial interaction for model development and new
strategies of gene therapy for prostate cancer and osteosarcoma metastases. Gene Therapy and
Molecular Biology 2:41-58, 1998.
5. Gardner TA, Raikwar SP, Kao C, Targeted Adenoviral Vectors II: Transcriptional Targeting, Chapter 9
Adenoviral Vectors for Gene Therapy Editors Curiel & Douglas, Academic Press ,2002.
6. Gardner TA, Transcriptional targeting of Adenoviral Vectors, Science & Medicine May/June 2002.
7. Jimenez JA, Kao C, Lee SJ, Jung C, Gardner TA: Gene Therapy for Prostate Cancer, Chapter 4,
Prostate Cancer, Basic Mechanisms and Therapeutic Approaches, Editor Chang, World Scientific
Publishing Co., 2005.
8. Gardner TA, Jimenez JA, Chung LWK, Kao C, Antimetastatic Gene Therapy: Prostate Cancer Theory
to Therapy, Chapter 20, Cancer Gene Therapy, Editors Curiel & Douglas, Humana Press, 2005.
9. Jimenez JA,LI X, Gardner TA, Kao C: Gene Therapy for Advanced Prostate Cancer, Chapter
9, Prostate Cancer, Biology, Genetics and New Therapuetics, Editors Chung, Isaacs &Simons
Humana Press 2007.
10. Jacobsen NB and. Gardner TA: Overcoming the Stigma of Complications of Continent Cutaneous
Diversion. Chapter 22 Bladder Cancer: Moving the Field Forward Edited by Lee/Wood, 2009.
11. Jacobsen NB and Gardner TA: Advances in Gene Therapy for Bladder Cancer,Chapter 31,Bladder
Cancer: Moving the Field Forward Edited by Lee/Wood, 2009
P&T Dossier CV 03/2010
Page
18
Thomas A. Gardner, M. D.
Abstract Poster and Oral Presentations (52 of 97 in rank)
1. Gardner TA. Vascular extension of renal cell carcinoma into the inferior vena cava: An institutional
experience. Presented at the Ferdinand C. Valentine Essay Contest, New York Section of the American
Urologic Association, New York, NY, March 1993.
2. Gardner TA, Fair WR, Sogani PC, Bains MS, Herr HW, Morse M, Russo P, Sarkis A, Sheinfeld J,
Whitmore WF Jr., Burt M. Renal cell carcinoma with inferior vena caval involvement: A Memorial
Sloan-Kettering Cancer Center experience. Presented at the 89th annual meeting of the American
Urologic Association, San Francisco, CA, May 1994. J Urol 151:262A (Abstract #138).
3. Gardner TA, Li PS, Lopez M, Wright EJ, Goldstein M. Development of a rat model for microsurgical
vasoepididymostomy: Effect of vasectomy technique and occlusion time on epididymal dilation.
Presented at the 50th annual meeting of the American Fertility Society, San Antonio, TX, November
1994 (Abstract P-244, pS201).
4. Gardner TA, Li PS, Lopez M, Wright EJ, Goldstein M. Microsurgical vasoepididymostomy: A
comparison of end to end, end to side, and tubular pull through techniques in the rat. Presented at the
50th annual meeting of the American Fertility Society, San Antonio, TX, November 1994 (Abstract P254, pS205).
5. Gardner TA. Flexible peritoneoscopy for the diagnosis of the contralateral hernia at the time of
unilateral pediatric herniorrhaphy. Presented at the Ferdinand C. Valentine Essay Contest, New York
Section of the American Urologic Association, New York, NY, March 1995.
6. Gardner TA, Li PS, Eid JF, Goldstein M. Rectal probe electroejaculation for obtaining semen in rats.
Presented at the 90th annual meeting of the American Urologic Association, Las Vegas, Nevada, April
1995. J Urol 153:499A, (Abstract #1080).
7. Gardner TA, Hajdu S, Waldbaum R, Badillo F, Steckel J. Can cancer volume on prostate needle
biopsies accurately predict the pathological stage of radical prostatectomy specimens? Presented at 93rd
Annual meeting of the New York Section of the American Urologic Association, Istanbul, Turkey,
October 1995.
8. Gardner TA, Mininberg DT. Update on flexible peritoneoscopy for the diagnosis of the contralateral
hernia at the time of unilateral pediatric herniorrhaphy. Presented at 93rd Annual meeting of the New
York Section of the American Urologic Association, Istanbul, Turkey, October 1995.
9. Gardner TA, Lemer ML, Schlegel PN, Waldbaum RS, Steckel J, Vaughan ED. Does microfocal
prostate cancer on needle biopsy predict pathologic stage or clinical course? Presented at the Sixth
International Prostate Cancer Update. Beaver Creek, Colorado, February 1996.
10. Matthews GJ, Gardner TA, Eid JF. In vitro fertilization with intracytoplasmic sperm injection (ICSI)
improves pregnancy rates for electroejaculated sperm. Presented at the 91st annual meeting of the
American Urologic Association, Orlando, Florida, May 1996. J Urol 155:368A, (Abstract #230).
11. Kao C, Ko SC, Cheon J, Gardner TA, Gotoh A, Shirakawa T, Sikes RA, Karsenty G, Chung LWK.
Osteocalcin promoter-based toxic gene therapy for the treatment of osteosarcoma and prostate cancer in
experimental models. Presented at the 7th Prouts Neck Meeting on Prostate Cancer: NCI-sponsored
Conference on the Biology and Treatment of Prostate Cancer. Prouts Neck, ME, October 1996.
12. Gardner TA, Thornhill KE, Goldstein M. Preoperative prediction of testicular biopsy: Pitting the
infertility specialist against the neural network. Presented at the 52nd annual meeting of the American
Society for Reproductive Medicine, Boston, MA, November 1996. (Abstract O-98, pS50).
13. Gardner TA, Boyd S, Theodorescu D. Factors determining length of stay after radical prostatectomy: A
comparison of perineal and retropubic approach. Presented at the American Cancer Society Annual
Regional Meeting of Virginia, Richmond, VA, March 1997.
14. Cheon J, Ko S-C, Gardner TA, Shirakawa T, Kao C and Chung LWK. Chemogene therapy: Osteocalcin
promoter based suicide gene therapy in combination with methotrexate in a murine osteosarcoma model.
Presented at the American Cancer Society Annual Regional Meeting of Virginia, Richmond, VA, March
1997.
P&T Dossier CV 03/2010
Page
19
Thomas A. Gardner, M. D.
15. Gardner TA, Lemer ML, Schlegel PN, Waldbaum R, Vaughan ED Jr., Steckel J. Microfocal prostate
cancer: Biopsy volume does not predict actual tumor volume. Presented at the 92nd annual meeting of
the American Urologic Association, New Orleans, LA, April 1997. J Urol 157:295 (Abstract #1148).
16. Gardner TA, Kao C, Ko SC, Cheon J, Wu TT, Cui Q, Balian G, Chung LWK. Prostate cancer cell
killing using a genetically modified bone stroma cell: Transforming friend to foe with gene therapy.
Presented at the 92nd annual meeting of the American Urologic Association, New Orleans, LA, April
1997. J Urol 157:268 (Abstract #1041).
17. Cheon J, Ko SC, Gardner TA, Kao C, Shirakawa T, Chung LWK. Vitamin D3-enhanced osteocalcin
promoter-based gene therapy: A novel approach for the treatment of prostate cancer and its metastasis.
Presented at the 92nd annual meeting of the American Urologic Association, New Orleans, LA, April
1997. J Urol 157:223 (Abstract #870).
18. Shirakawa T, Cheon J, Ko SC, Gardner TA, Gotoh A, Kao C, Wu TT, Chung LWK. Development of
therapeutic toxic gene therapy in experimental models of human prostate cancer bone metastasis:
Osteocalcin promoter-based toxic gene therapy. Presented at the 92nd annual meeting of the American
Urologic Association, New Orleans, LA, April 1997. J Urol 157:22 (Abstract #86).
19. Gardner TA, Boyd S, Theodorescu D. Factors determining length of stay after radical prostatectomy: A
comparison of perineal and retropubic approach. Presented at the 83rd annual clinical congress of the
American College of Surgeons, Chicago, IL, October 1997.
20. Kao C, Ko SC, Shirakawa T, Gardner TA, Ou YC, Cheon J, Zhau HE, Chung LWK. Tissue specific
toxic gene therapy for androgen-independent human prostate cancers. Presented at the Keystone
Symposia on Molecular and Cellular Biology of Gene Therapy, Keystone, CO, January 1998.
21. Sokoloff MH, Gardner TA, Caven TH, Wood A, Chung LWK. Induction of human prostate cancer
differentiation by Vitamin-D analogues is attenuated by bone stromal and extracellular matrix cells.
Presented at the 1998 International Symposium on Biology of Prostate Growth, NIH, Bethesda, MD,
March, 1998 (Proceedings p101).
AACR 1998
22. Shirakawa T, Kao C, Ko SC, Gardner TA, Cheon J, Miyamoto T, Gotoh A, Kamidono S, Chung LWK.
Intravenous osteocalcin promoter based toxic gene therapy for the suppression of osteosarcoma
pulmonary metastasis. Presented at the 89th annual meeting of the American Association for Cancer
Research, New Orleans, LA, March 1998. Proceedings of the AACR 39:512 (Abstract #3487).
ASGT 1998
23. Gardner TA, Kao C, Shirakawa T, Ko SC, Woo S, Dasarathy Y, Eriksson K, Chung LWK. Adenoviral
bystander gene therapy: Cytosine deaminase with 5-flurocytosine is superior over thymidine kinase with
acyclovir in the treatment of human renal cell carcinoma in a mouse model. Presented at the 1st annual
meeting of the American Society of Gene Therapy, Seattle WA, May 1998 (Abstract #429).
24. Kao C, Kaneda Y, Liu D, Ko SC, Burt M, Ginsberg RJ, Chung LWK, Gardner TA. Locoregional
delivery of Ad-CMV-TK combined with ganciclovir is an effective therapy for the treatment of sarcoma
pulmonary metastases. Presented at the 1st annual meeting of the American Society of Gene Therapy,
Seattle, WA, May 1998 (Abstract #427).
25. Gardner TA, Ko SC, Kao C, Kim SJ, Ou YC, Cui Q, Balian G, Chung LWK. Application of
osteoblastic tissue-specific promoter and bone homing mechanism to deliver therapeutic toxic genes for
the treatment of prostate cancer metastasis. Presented at the 1st annual meeting of the American Society
of Gene Therapy, Seattle, WA, May 1998 (Abstract #432).
26. Ko SC, Gardner TA, Shirakawa T, Cheon J, Miyamoto T, Gotoh A, Chung LWK, Kao C. Effective
systemic delivery of adenoviral vectors: targeting pulmonary metastases safely with a tumor-specific
promoter. Presented at the 1st annual meeting of the American Society of Gene Therapy, Seattle, WA,
May 1998 (Abstract #426).
27. Ko SC, Alden TD, Kim SJ, Sheehan JP, Hankins GR, Gardner TA, Know A, Kao C, Kallmes DF, Cloft
HJ, Helm GA. The treatment of malignant meningiomas using osteocalcin promoter based gene therapy.
Presented at the 1st annual meeting of the American Society of Gene Therapy, Seattle WA, May 1998
(Abstract #417).
AUA 1998
P&T Dossier CV 03/2010
Page
20
Thomas A. Gardner, M. D.
28. Gardner TA, Ko SC, Kao C, Cui Q, Balian G, Chung LWK. Exploiting prostate cancer-bone stromal
interaction with gene therapy: Application of osteoblastic tissue-specific promoter and bone homing
mechanism to deliver therapeutic toxic genes for the treatment of prostate cancer metastasis. Presented at
the 93rd annual meeting of the American Urologic Association, San Diego, CA, June 1998. J Urol 159:4
(Abstract #16).
******1998 AUA Essay Contest Co-First Prize in Research Category****
29. Sokoloff MH, Gardner TA, Boyd JC, Theodorescu D. Surgical approach and pain management affect
length of stay in radical prostatectomy patients. Presented at the 93rd annual meeting of the American
Urologic Association, San Diego, CA, June 1998. J Urol 159:301 (Abstract #1161).
30. Shirakawa T, Gardner TA, Kao C, Ko SC, Miyamoto T, Bander NH, Woo S, Chung LWK. Ablative
gene therapy of human renal cell carcinoma: Cytosine deaminase plus 5-flurocytosine has superior
bystander effect over thymidine kinase plus acyclovir. Presented at the 93rd annual meeting of the
American Urologic Association, San Diego, CA, June 1998. J Urol 159:147 (Abstract #558).
31. Ou YC, Gardner TA, Ko SC, Zhau HE, Kao C, Yeung F, Aprikan AG, Chung LWK. Expression of
osteocalcin by primary and metastatic prostate cancer and human prostate cell lines: A novel therapeutic
target for prostate cancer metastasis. Presented at the 93rd annual meeting of the American Urologic
Association, San Diego, CA, June 1998. J Urol 159:2 (Abstract #6).
32. Rhee HW, Chang S, Gardner TA, Chung LWK. Three-dimensional human prostate organoid culture to
study cell-cell and cell-matrix interaction: Irreversible alterations of prostate epithelial tumorigenicity,
growth responsiveness to androgen and estrogen, and growth factors in culture. Presented at the 93rd
annual meeting of the American Urologic Association, San Diego, CA, June 1998. J Urol 159:5
(Abstract #17).
33. Cheon J, Kim JJ, Koh SK, Ko SC, Gardner TA, Kao C, Chung LWK. Adenovirus-mediated suicide
gene therapy for the treatment of orthotopic murine bladder tumors. Presented at the 93rd annual meeting
of the American Urologic Association, San Diego, CA, June 1998. J Urol 159:284 (Abstract #1093).
34. Gardner TA, Cui Q, Kao C, Ko S-C, Cheon J, Wu TT, Chung LWK, Balian G. Pluripotential cells form
bone marrow stroma deliver therapeutic genes to bone metastases. Presented at the 45th annual meeting
of the Orthopaedic Research Society, Anaheim, CA, February 1999.
KUA 1998
35. Cheon J, Kim HK, Shim GS, Kim YS, Koh SK, Ko SC, Gardner TA, Kao C, Chung LWK.
Development of novel medical prostatectomy for the treatment of benign prostatic hyperplasia: Change
of Histopathological tumor markers and effect on prostrate volume. Korea Urological Association, 1998,
Seoul Korea.
AACR 1999
36. Wada Y, Gardner TA, Ko SC, Kao C, Kim SJ, Shirakawa T, Chung LWK. Widening the therapeutic
window of thymidine kinase/GCV gene therapy with a tumor-restricted promoter: Osteocalcin based TK
gene therapy for osteosarcoma. Minisymposium presentation at the 90th annual meeting of the AACR,
Philadelphia,PA, April 1999. Proceedings of the AACR 40:87 (Abstract #579).
AUA 1999
37. Cheon J, Kim HK, Shim GS, Koh SK, Ko SC, Gardner TA, Zhau HE, Kao C, Chung LWK. Ablation of
murine prostate utilizing ad-oc-tk/gcv treatment: a potential molecular therapy for the treatment of benign
prostatic hyperplasia. Presented at the 94th annual meeting of the American Urologic Association,
Dallas, TX, May 1999. J Urol 161:305 (Abstract #1174).
38. Cheon J, Moon DG, Kim JJ, Kim HK, Koh SK, Ko SC, Gardner TA, Kao C, Chung LWK, Woo SL.
Effect of adenovirus-mediated suicde gene therapy on long-term host survival in an orthotopic murine
bladder tumor model. Presented at the 94th annual meeting of the American Urologic Association, Dallas,
TX, May 1999. J Urol 161:115 (Abstract #435).
39. Shirakawa T, Gotoh A, Fujisawa M, Okada H, Arakawa S, Kamidono S, Gardner TA, Wada Y, Kao C.
Development of human chorionic gonadotoropin subunit ß (ß-hcg) promoter-based toxic gene therapy for
testicular germ cell tumor. Presented at the 94th annual meeting of the American Urologic Association,
Dallas, TX, May 1999. J Urol 161:183 (Abstract #706).
P&T Dossier CV 03/2010
Page
21
Thomas A. Gardner, M. D.
40. Shirakawa T, Matsubara S, Gotoh A, Fujisawa M, Okada H, Arakawa S, Kamidono S, Gardner TA,
Wada Y, Ko SC, Kao C. Molecular therapy with recombinant wt-p53 adenovirus for the treatment of
benign prostatic hyperplasia in human cells and rat experimental models. Presented at the 94th annual
meeting of the American Urologic Association, Dallas, TX, May 1999. J Urol 161:359 (Abstract #1391).
41. Ou YC, Yeung F, Yang L, Kao C, Chung LWK, Gardner TA. MN promoter activity in renal cell
carcinoma cell lines: a potential for tissue restrictive gene therapy. Presented at the 94th annual meeting
of the American Urologic Association, Dallas, TX, May 1999. J Urol 161:145 (Abstract #554).
42. Kim SJ, Gardner TA, Ko SC, Kao C, Balian G, Chung LWK. Enhancement of bystander prostate
cancer cell killing by the utilization of genetically engineered bone stromal cells that confer either
cytosine deaminase or thymidine kinase gene. Presented at the 94th annual meeting of the American
Urologic Association, Dallas, TX, May 1999. J Urol 161:58 (Abstract #217).
43. Ou YC, Gardner TA, Ko SC, Zhau HE, Kao C, Chung LWK, Water D. Expression of osteocalcin in
canine metastatic prostate cancer : an ideal prostate cancer animal model for osteocalcin promoter-based
toxic gene therapy.Presented at the 94th annual meeting of the American Urologic Association, Dallas,
TX, May 1999. J Urol 161:130 (Abstract #498).
44. Caven TH, Sokoloff MH, Chang SM, Gardner TA, Wood A, Chung LWK. Inhibition of human prostate
cancer growth by vitamin-D analogues is attenuated by increaseds in stromal and extracellular matrix
factors. Presented at the 94th annual meeting of the American Urologic Association, Dallas, TX, May
1999. J Urol 161:296 (Abstract #1136).
45. Eriksson K, Gardner TA, Dasarathy Y. Purification of adenoviral vectors using anion exchange
chromatography. Presented at the 19th International Symposium on the Separation of Proteins, Peptides
and Polynucleotides, Delray Beach, FL, October-November 1999.
46. Ou, T-c, Yeung F, Kao C, Chung LWK, Gardner TA. Expression of MN in renal cell carcinoma cell
lines: A potential for tissue restrictive gene therapy. Presented at the First International Kidney Cancer
Symposium, Chicago, IL, October 1999.
47. Gardner TA, Wada Y, Shirakawa T, Ko S-C, Kao C, Kim SJ, Yang L, Chung LWK. Osteocalcin
promoter restricted adenoviral replication as a potential treatment of prostate cancer metastasis. Presented
at the 8th International Conference on Gene Therapy of Cancer, San Diego, CA, December 1999.
**************1999 Vical Best Abstract Award ************
ASGT 2000
48. Gardner TA, Chung LWK, Koenemen K, Gillenwater JY, Myers C, Fisch M, Kallmes D, Wada Y,
Yang, L, Kao, C. Preliminary safety report of an osteocalcin-based adenoviral gene therapy (Ad-OC-TK)
for metastatic and recurrent prostate cancer: Tumor-restrictive promoter confers safety of toxic gene
expression. Presented at 3rd annual meeting of the American Society of Gene Therapy, May 2000. Mol
Therapy 1(5):S236 (Abstract # 649).
49. Matsubara S, Wada Y, Hsieh CL, Gardner TA, Shirakawa T, Gotoh A, Kao C, Kamidono S, Chung
LWK. Tissue-specific osteocalcin (OC) promoter-based replication-competent adenovirus gene therapy
for human prostate cancer skeletal metastasis models. Presented at 3rd annual meeting of the American
Society of Gene Therapy, May 2000. Mol Therapy 1(5):S151 (Abstract # 390).
50. Koeneman KS, Gardner TA, Chung LWK, Masik GB. Mechanism of elevated aPT during
administration of adenoviral vectors for gene therapy. Presented at 3rd annual meeting of the American
Society of Gene Therapy, May 2000. Mol Therapy 1(5):S54 (Abstract # 108).
NCS 2000
51. Gardner TA, Sanghvi NT, Koch MO, Bihrle R, Foster R Improved Prostatic Ablation using a Split Beam
Modification of the High Intensity Focused Ultrasound(HIFU).”, Proceeding of 74th Annual North Central
Section of AUA, p49.
52. Gardner TA, Koeneman K, Gillenwater J, Koch M, Chung LWK, Kao C “Osteocalcin Based Gene
therapy for the treatment of Metastatic Prostate Cancer. Phase I results and Phase II trial Design.”.
Proceeding of 74th Annual North Central Section p75.
ASGT 2001
P&T Dossier CV 03/2010
Page
22
Thomas A. Gardner, M. D.
53. Gardner TA, Shalhav M, Kim HS, Ou YC, Kin SJ, Kao C “Preclinical Evaluation of Renal Cell
Carcinoma Specific-Oncolysis using MN Promoter Mediated Transcriptional Targeting”,” Molecular
Therapy 3(5):S348,2001.
AUA 2001
54. Matsubara S, Wada Y, Gardner TA, Hsieh CL, Zhau HE, Kao C, Gillenwater JY, Chung LWK,
Kamidono S. ``Systemic Osteocalcin (OC) Promoter-Driven replication-competent Adenovirus for the
treatment of androgen-independent prostate cancer bone metastasis.” J Urol 165(5):S45,2001( Abstract
#183)
55. Cheon J, Park HS, Bae JH, Moon DG, Kim JJ, Cho HY, Gardner TA, “In-vivo characterization of a
prostate specific antigen promoter-based suicide gene therapy for the treatment of benign prostatic
hyperplasia” J Urol 165(5):S113,2001( Abstract #462)
56. Masterson T, Koch MO, Foster R, Bihrle R, Wahle G, Gardner TA, Cheng L. “Does more extensive
prostate sampling more accurately predict tumor characteristics” J Urol 165(5):S241,2001( Abstract #992)
57. Gardner TA, Koch MO, Shalhav A, Bihrle R, Foster R, Murphy J, Rao VV, Sanghvi N, Resnick MI,
Seftel AD, Grunberger I, Steidel CP, Corhran JS. “High intensity focused ultrasound (HIFU) for the
treatment of BPH: Interim results of A Multicenter phase III study.” J Urol 165(5):S369,2001( Abstract
#1512)
58. Raikwar SP, Sandoval R, Moghaddam M, Molitoris B, Kao C, Gardner TA. Intravital dual photon
confocal optical imaging of a fluorescent prostate tumor model. New Discoveries in Prostate Cancer
Biology and Treatment (AACR Sponsored) Abstract #
NCS 2001
59. Shalhav Al, Stevens LH, Gardner TA, Koch MO, Lingeman JE, “Factors recommended to improve
laparoscopic donor nephrectomy outcomes” Proceeding of 75th Annual North Central Section p101.
60. Shalhav Al, Stevens LH, Gardner TA, Lingeman JE, “Modified pfannenstiel for manual
specimen retrieval without a pneumoperitoneum preserving device following pure
laparoscopic live donor nephrectomy.” Proceeding of 75th Annual North Central Section
p103.
61. Zhang S, Goebl MG, Harrington MA, Gu J, Kao C, Gardner TA, Eble JN, Cheng L: MyoD
expression blocks tumor initiation in the murine RM-9 prostate tumor model. Presented at the
2001 annual meeting of the United States and Canadian Academy of Pathology in Atlanta,
GA. Modern Pathol 14:130A, 2001.
62. Zhang S, Gu J, Wilkes DS, Woods K, Kao C, Gardner T, Eble JN, Cheng L: Tumor extract
pulsed IL-12 stably transfected dendritic cells blocked the formation of prostatic carcinoma in
vivo. Presented at the 2001 annual meeting of the United States and Canadian Academy of
Pathology in Atlanta, GA. Modern Pathol 14:130A, 2001.
63. Zhang S, Gu J, Kao C, Gardner T, Eble JN, Cheng L: IL-12 antitumor effect is mediated by
Fas-Fas ligand induced apoptosis. Presented at the 2001 annual meeting of the United States
and Canadian Academy of Pathology in Atlanta, GA. Modern Pathol 14:131A, 2001.
64. Raikwar S.P., Sandoval, R.M., Moghaddam, M., Molitoris, B.A., Kao, C. and Gardner, T.A.
(2001): Intravital dual photon Confocal optical imaging of a fluorescent prostate tumor
model. New Discoveries in Prostate Cancer Biology and Treatment. Naples, Florida,
December 2001. ***American Association for Cancer AACR-Astra-Zeneca Scholar-intraining award (2001)***
AACR 2001
65. Zhang S, Gu J, Kao C, Gardner TA, Eble JN, Cheng L: Fas-Fas ligand mediated apoptosis
in IL-12 induced rejection of prostate tumor. Presented at the 92nd annual meeting of the
American Association for Cancer Research in New Orleans, LA. Proc Am Assn Cancer Res
42:72; 2001.
66. Cheng L, Zhang S, Goebl MG, Harrington MA, Gu J, Kao C, Gardner TA, Eble JN: MyoD
expression blocks tumor initiation in the murine RM-9 prostate tumor model. Presented at the
P&T Dossier CV 03/2010
Page
23
Thomas A. Gardner, M. D.
92nd annual meeting of the American Association for Cancer Research in New Orleans, LA.
Proc Am Assn Cancer Res 42:72; 2001.
ASGT 2002
67. Lee S-J, Kim H-S, Rong Y, Gardner TA, Kao C. “Novel Chimeric Prostate-Specific Promoter, PSESBased Suicide Gene Therapy Demonstrates Specific Killing in Human Prostate Cancer Cells”," 5th
Annual Meeting of the American Society of Gene Therapy, June 8, 2002, Boston, Massachusetts.
68. 463] Development of a Novel Adenoviral Vector for Real Time Monitoring of VP22 Mediated
Intercellular Trafficking in Prostate, Renal and Breast Cancer Cell Lines Sudhanshu P. Raikwar, Chinghai
Kao, Thomas A. Gardner. 5th Annual Meeting of the American Society of Gene Therapy, June 8, 2002,
Boston, Massachusetts.
69. Kubo H, Gardner TA, Gotoh A, Koeneman KA, Lim S, AminMB, Gillenwater JW, Yang H, Wada Y,
Nakagawa M, Kao C, Zhau HE, Chung LWK. UrologyCorrelation of Therapeutic Responses with Tumor
Associated Parameters: A Phase I Clinical Trial of Adenovirus Osteocalcin Promoter Driven Herpes
Simplex Virus Thymidine Kinase (Ad-OC-TK) for Metastatic and Localized Hormone Refractory
Prostate Cancer[Oral #1174] 5th Annual Meeting of the American Society of Gene Therapy, June 8,
2002, Boston, Massachusetts.
70. Gardner TA, Brandli DW, Shalhav M, Shalhav T, Kim HS, Kao C. Renal Cell Carcinoma-Specific
Oncolysis Mediated by MN-Promoter Based Transcriptional Regulation of Adenoviral E1a
Protein[Poster1285] 5th Annual Meeting of the American Society of Gene Therapy, June 8, 2002,
Boston, Massachusetts.
71. Gardner TA, Raikwar SP, Krasnykh V, Kao C. Combining Transductional-Targeting with TranslationalTargeting for Prostate Cancer Adenoviral-Mediated Oncolytic Effect 653] 5th Annual Meeting of the
American Society of Gene Therapy, June 8, 2002, Boston, Massachusetts.
72. Raikwar SP, Sandoval RM, Kim HS, Kao C, Molitoris BA, Gardner TA. Intravital Confocal Fluorescence
Optical Imaging of VP22-Mediated Intercellular Trafficking and Tumor Vasculature Targeting in the
Prostate Tumor Models. oral #1189 at 5th Annual Meeting of the American Society of Gene Therapy,
June 8, 2002, Boston, Massachusetts.
AUA 2002
73. Brandli DW, Shalhav M, Shalhav T, Kim H-S, Kao C, Gardner TA. MN-Based transcriptional
regulation of adenoviral early proteins provides renal cell carcinoma-specific oncolysis. J Urol
167(4):S132, 2002 (AUA 2002 Abstract #529).
74. Shalhav Al, Siqueira TM, Stevens LH, Gardner TA, Lingeman JE, Koch ME “A Modified pfannenstiel
incision for manual retrieval without a pneumoperitoneum-preserving device following pure laparoscopic
live donor nephrectomy.” J Urol 167(4):S394, 2002(AUA 2002 Abstract #v1569).
****Best Video Award – Honorable Mention****
ISTU 2002
75. Uchida T, Sanghvi NT, SatohT, Irie A, Omata T, Baba S, Koch MO, Gardner TA, "Transrectal High
Intensity Focused Ultrasound for the Treatment of Localized Prostate Cancer," Proc. of the International
Symposium on Therapeutic Ultrasound, 2002.
76. Sanghvi NT, Uchida T, Koch MO, Gardner TA, "Total Prostate Ablation for the Treatment of Localized
Prostate Cancer Using Image Guided HIFU," presented at the 2002 IEEE Ultrasonics Symposium.
77. R. Seip, N.T. Sanghvi, R. Carlson, J. Tavakkoli, K. Dines, T.A. Gardner, and T. Uchida,
"Sonablate®500: A Novel Platform for Transrectal Image-Guided HIFU Treatment of
Localized Prostate Cancer," presented at the 32nd Annual Symposium of the Ultrasonic
Industry Association (UIA), 2002.
AACR 2002
78. Cheng L, Jiang J, Zhang S, Kao, C, Gardner TA, Eble JN: Fas and Fas ligand expression is
elevated in prostatic intraepithelial neoplasia and prostatic adenocarcinoma. Presented at the
93nd annual meeting of the American Association for Cancer Research in San Francisco, CA.
Proc Am Assn Cancer Res 43:1 (abstract No. 3A); 2002.
ISTU 2003
P&T Dossier CV 03/2010
Page
24
Thomas A. Gardner, M. D.
79. J. Tavakkoli, A. Mehta, C. Miller, R. Seip, N.T. Sanghvi, L. Cheng, T.A. Gardner, and A.L. Shalhav, "A
Laparoscopic HIFU Probe with Integrated Phased Array Ultrasound Imaging," to appear in the
International Symposium on Therapeutic Ultrasound, 2003.
80. R. Seip, D. Shaeffer, P. Lawrence, T.A. Gardner, M.O. Koch, L. Cheng, A. Wunderlich, C. Miller, and
N.T. Sanghvi, "Feasibility Study for the Treatment of Brachytherapy Failure Prostate Cancer using HighIntensity Focused Ultrasound," to appear in the International Symposium on Therapeutic Ultrasound,
2003
AUA 2003
81. Lee S, Kim HS, Jung C, Gardner TA, Kao C. NFATC1 with AP-3 site binding specificity mediates gene
expression of prostate specific membrane-antigen. AUA 2003 #207P
82. Gardner TA,Lee SJ, Mosharafa A, Lee X, Yu R, Cheng L, Kim HS, Jung C, Kao C. Generation of a
Prostate-restricted replication competent adenovirus using a chimeric prostate specific promoter AUA
#830.
83. Kubo H, Gardner TA, Wada Y, Koeneman KS, Gotoh A, Ling Y, Kao C, Lim SD, Amin MB, Yang H,
Black ME, Matsubara S, Nakagawa M, Gillenwater JY, Zhau HE, Chung LWK. Phase I dose-escalation
clinical trial of adenoviral osteocalcin promoter driven herpes simplex virus thymidine kinase in localized
and metastatic hormone refractory prostate cancer #940
84. Gardner TA, Koch MO, Shalhav AL, Foster RS, Bihrle R, Resnick MI, Seftal AD, Grunberger I, Steidle
CP, Cochran JS, Sanghvi NT. Phase III multicenter study of high intensity focused ultrasound (HIFU) for
the treatment of benign prostatic hypertrophy (BPH): Final Analysis.:Abstract 1453 oral
ASGT 2003
85. Raikwar SP, Gardner TA, Kao C. Antiangiogenic gene therapy targeting the endothelium-specific Flk-1
and Tie-2: Inhibition of tumor angiogenesis and growth in prostate cancer. ASGT 2003 #337, Molecular
therapy 7(5): S132, 2003.
86. Gardner TA, Zhang Y, Lee SJ, Kim HS, Kao C. Replication-competant adenovirus targeting prostate
using PSMA enhancer. ASGT 2003 #936, Molecular therapy 7(5): S360, 2003.
87. Raikwar SP,Kao C, Gardner TA. An adenoviral vector expressing a novel chimeric endostatinangiostatin gene inhibits angiogenesis and tumor growth in prostate cancer. ASGT 2003 #1112,
Molecular therapy 7(5): S428, 2003.
APA 2004
88. Armatys S, Koch MO, Bihrle R, Gardner TA, Eble JN, Patel NB, Daggy JB, Cheng L: A
clinicopathologic comparison of clinical sages T1c versus T2 prostate adenocarcinoma: lack
of difference in PSA recurrence. Presented at the 2004 annual meeting of the United States
and Canadian Academy of Pathology in Vancouver, B.C., Canada. Modern Pathol 17: 573A,
2004.
89. Bunde PJ, Koch MO, Bihrle RA, Gardner TA, Eble JN, Daggy J, Cheng L: Preoperative
PSA is correlated with tumor volume and prostate weight and predictive of PSA recurrence.
Presented at the 2004 annual meeting of the United States and Canadian Academy of
Pathology in Vancouver, B.C., Canada. Modern Pathol 17: 596A, 2004.
90. Hong H, Kao C, Jeng M, Eble JN, Koch MO, Gardner TA, Zhang S, Li L, Hu Z,
MacLennan GT, Cheng L: Overexpression of CARM1, a transcriptional coactivator of
androgen receptor, in prostatic adenocarcinoma and its precursors. Presented at the 2004
annual meeting of the United States and Canadian Academy of Pathology in Vancouver,
B.C., Canada. Modern Pathol 17: 660A, 2004.
91. Sweeney C, Li L, Bhat-Nakshatri P, Baldridge LA, Zhang S, Gardner T, Kao C, Koch MO,
Nakshatri H, Cheng L: Nuclear factor kappa b is constitutively activated in prostate cancer in
vitro and is increased in prostatic intra-epithelial neoplasia and adenocarcinoma of the
prostate. Presented at the 2004 annual meeting of the United States and Canadian Academy
of Pathology in Vancouver, B.C., Canada. Modern Pathol 17: 750A, 2004.
AUA 2004
P&T Dossier CV 03/2010
Page
25
Thomas A. Gardner, M. D.
92. Gardner TA, Raikwar SP, Lee SJ, Bunde PJ, Xiong L, Kao C. Ad-PSES –TRAIL: A novel
Prostate specific TRAIL over-expressing adenoviral vector for androgen independent prostate
cancer gene therapy. AUA 2004 # 616P
93. Bunde PJ, Koch MO, Bihrle R, Gardner TA, Eble JN, Daggy JK, Cheng L. Preoperative
prostatic specific antigen is correlated with tumor volume and prostate weight and predictive
of biochemical recurrence. (AUA 2004 # 1263 Oral)
94. Zeng G, Hu Z, Zhang S, Li L, Baldridge LA, Kao C, Gardner TA, Koch MO, Ulbright TM,
Eble JN, Cheng L. EPHA2: A novel target for prostate cancer treatment. (AUA 2004 #1823
P)
ASGT 2004
95. Toshiro Shirakawa, Nobuyuki Hinata, Shuji Terao, Katsumi Shigemura, Naonori Taniguch, Kazuhito
Fukushima, Khoji Sugimoto, Kazuro Sugimura, Masafumi Matsuo, Sakan Maeda, Sadao Kamidono,
Chinghai Kao, Thomas A. Gardner, Leland W. K. Chung, Akinobu Gotoh. Phase I/II Clinical Trial of
Ad-OC-TK plus VAL for the Patients with Metastatic or Local Recurrent Prostate Cancer: Initial
Experience in Japan7th Annual American Society of Gene Therapy, June 4, 2004, Minneapolis, Minnesota
(Poster #604). Molecular Therapy 9 (1): S228, 2004.
96. Sudhanshu P. Raikwar, Chinghai Kao, Thomas A. Gardner Synergy between Angiostatin-Endostatin
and Tie-2: A Novel Anti-Angiogenic Gene Therapy for Prostate Cancer ,7th Annual American Society of
Gene Therapy, June 5, 2004, Minneapolis, Minnisota(Poster #966). Molecular Therapy 9 (1): S369,2004.
97. Sudhanshu P. Raikwar, Thomas A. Gardner, Chinghai Kao. VP22 Mediates Tumor Vasculature Specific
Targeting 7th Annual American Society of Gene Therapy, June 6, 2004, Minneapolis, Minnesota (Oral
Abstract #1021) Molecular Therapy 9 (1): S391,2004.
ASGT 2005 (St-Louis)
98. Xiong Li, Yang Ping Zhang, Hong-Sup Kim, Kyung-Hee Bae, Keith M. Stantz, Sang-Jin Lee, Chaeyong
Jung, Jaun A. Jimenez, Thomas A. Gardner, Meei-Huey Jeng, Chinghai Kao. Gene therapy for prostate
cancer by controlling Adenovirus E1a and E4 Gene Expression with PSES. 8th Annual American Society of
Gene Therapy, June 6, 2005, St. Louis, Missouri,(Oral Abstract #1009) Molecular Therapy 9 (1):
S391,2005.
ASGT 2006 (Baltimore)
99. Xiong Li, Sudhanshu P. Raikwar, You-Hong Liu, Sang-Jin Lee, Yan-Ping Zhang, Shaobo Zhang, Liang
Cheng, Sang-Don Lee, Beth Elisa Juliar, Thomas A. Gardner, Meei-Huey Jeng, Chinghai Kao.
Combination Therapy of Androgen-Independent Prostate Cancer Using a Prostate Restricted Replicative
Adenovirus and a Replication-Defective Adenovirus Encoding Human Endostatin-Angiostatin Fusion
Gene (Oral Abstract #433)
AUA 2006 Alanta Vol. 558 175, No. 4, Supplement
100.Pratik Desai, Chandru P Sundaram, Xianhui Su, Thomas A Gardner, Michael Koch. ROBOTIC
ASSISTED LAPAROSCOPIC PROSTATECTOMY VS. OPEN RADICAL RETROPUBIC
PROSTATECTOMY: CHARACTERISTICS OF PATHOLOGIC POSITIVE SURGICAL MARGIN
Discussed Poster #1161 May 23, 2006
AUA 2007
101.Xiong Li, Sudhanshu P Raikwar, Sang-Jin Lee, Hong-Sup Kim, Shaobo Zhang, Thomas A Gardner,
Meei-Huey Jeng, Chinghai Kao. COMBINATION THERAPY OF ANDROGEN-INDEPENDENT
PROSTATECANCER USING A PROSTATE RESTRICTED REPLICATIVE ADENOVIRUS AND A
REPLICATION DEFICIENT ADENOVIRUS ENCODING HUMAN ENDOSTATIN-ANGIOSTATIN
FUSION PROTEIN Discussed Poster#806, May 22, 2006.
102.Matthew J Mellon*, Miwon Ahn, Yan-Ping Zhang, Juan A Jiménez, Chinghai Kao, Thomas A Gardner
ANTIANGIOGENIC GENE THERAPY FOR METASTATIC RENAL CELL CARCINOMA
PRODUCES TUMOR GROWTH SUPPRESSION IN AN ATHYMIC NUDE MOUSE
MODEL Podium Session at the 2007 Annual Meeting of the American Urological Association
Education and Research Anaheim, CA, May 19-24, 2007.
AACR 2007
P&T Dossier CV 03/2010
Page
26
Thomas A. Gardner, M. D.
103.Matthew J Mellon*, Miwon Ahn, Yan-Ping Zhang, Juan A Jiménez, Chinghai Kao, Thomas A Gardner
Metastatic renal cell carcinoma tumor growth suppression using adenoviral vectors expressing endostatinangiostatin fusion protein 2007 AACR Annual Meeting.
104.
P&T Dossier CV 03/2010
Page
27
Thomas A. Gardner, M. D.
P07-2
0807-01
Dendreon
D9902
0308-23
Dendreon
Corp.
PB01
0308-24
Dendreon
Corp.
P09-1
Dendreon
COU-AA302
P09-2
Gardner,
Thomas
CLOSED TO ACCR
consented, 16 enro
LTFU, 12 for F/U, 2
process of screenin
Gardner,
Thomas
CLOSED TO ACCR
follow for LTFU blo
Gardner,
Thomas
Gardner,
Thomas
CLOSED TO ACCR
Ferring
A Prospective Multicenter Registry of Salvage
Cryotherapy in Recurrent Prostate Cancer Study
the "Cold Registry"
An Open-Label, Multi-Center, Randomized,
Parallel-Arm One-Year Trial, Comparing the
Efficacy and Safety of Degarelix Three Month
Dosing Regimen with Goserelin Accetate in
Patient with Prostate Cancer Requiring Androgen
Deprivation Therapy
Cougar
Technology
A Phase 3, Randomized, Double-Blind, PlaceboControlled Study of Abiraterone Acetate (CB7630)
Plus Prednisonee in Asymptomatic or Mildly
Symptomatic Patients with Metastatic CastrationResistant Prostate Cancer
Gardner,
Thomas
Dendreon
An Open-Label Study of Sipuleucel-T in Men with
Metastatic Castrate Resistant Prostate Cancer
Gardner,
Thomas
Pre-selection visit l
Still waiting for the
the protocol.
In the process of o
Support from Dr. H
submitted to CTO a
on the budget
Koch,
Michael
This study will start
CLOSED TO ACCR
being follwed LTFU
Foster,
Richard
Close to accrual 3
intervention and int
Endocare
no funding
FE 200486
CS35
A Randomized, Multicenter, Single Blind Study in
Men with Metastatic Androgen Independent
Prostate Cancer to Evaluate Sipuleucel-T
Manufactured with Different Concentration of
PA2024 Antigen
A Randomized, Double Blind, Placebo Controlled
Phase 3 Trial of Immunotherapy With Autologous
Antigen Presenting Cells Loaded With PA2024
(Provenge, APC8015) in Men with Metastatic,
Androgen Independent Prostatic
Adenocarcinomas
An Open Label, Single Arm Trial of
Immunotherapy With Autologous Antigen
Presenting Cells Loaded with PA2024
(APC8015F) for Subjects with Objective Disease
Progression and Disease-Related Pain on
Protocol D9902 Part B
An Open-Label Study of Sipuleucel-T in Men with
Metastatic Castrate Resistant Prostate Cancer
Gardner,
Thomas
open to accrual, 1
Gardner,
Thomas
Pre-selection visit l
waiting for the ackn
protocol.
Koch
A Phase 4, Multicenter, Double-Blind, PlaceboControlled, Parallel Study of Alvimopan for the
Management of Postoperative Ileus in Subjects
Undergoing Radical Cystectomy
20090507
S2000
SWOG
Selenium and Vitamin E Cancer Prevention Trial.
Foster
0007-06
NIH
P&T Dossier CV 03/2010
Pilot Study: Cox-2 Inhibitor in Invasive Bladder
Cancer.
Page
28
Thomas A. Gardner, M. D.
Treatment Preferences and Health Outcomes in
Men With Clinically Localized Prostate Cancer. A
Prospective Cohort Study From the Prostate
Cancer Intervention Versus Observation Trial
(PIVOT) Registry
Foster,
Richard
Close to accrual, th
but still submits for
0704-79
Randomized Controlled Trial Examining the
Return of Urinary Continence After RobotAssisted Radical Prostatectomy with or Without a
Urethrovesical Sling
Comparison of Laparoscopic Versus HandAssisted Laparoscopic Donor Nephrectomy
Outcomes After Robotic-Assisted Laparoscopic
Pyloplasty
Prospective Study of Laparoscopic Renal and
Adrenal Surgery
The Effect of Robot Assisted Surgery on Patient
Selection of Urologic Treatments
Database of Patients Undergoing Kidney and
Adrenal Surgery
Chandru
Sundaram
Chandru
Sundaram
Chandru
Sundaram
Chandru
Sundaram
Chandru
Sundaram
IRB has been appr
received the contra
(Marv Andrews has
multiple times) nee
Do Continuing Sub
Amendments to IR
Do Continuing Sub
Amendments to IR
Do Continuing Sub
Amendments to IR
Do Continuing Sub
Amendments to IR
Do Continuing Sub
Amendments to IR
EX0403-34
Review of Laparoscopic Donor Nephrectomy and
Recipient Outcomes: The Indiana University
Experience
Chandru
Sundaram
Do Continuing Sub
Amendments to IR
Stephen
Beck
Do Continuing Sub
Amendments to IR
9903-35
Sundaram
0806-53
Cooks
Medical
0309-24
0309-52
0606-22
0610-64
Beck
0807-63
P&T Dossier CV 03/2010
Gene Expression Profiling-Based Prediction of
Systemic Metatases in Clinical Stage A
Nonseminom Germ Cell Tumors
Page
29
Thomas A. Gardner, M. D.